Amgen Inc. (AMGN)
Amgen Impresses With Q4 Earnings Beat, Analysts See Growth Ahead
On Tuesday, Amgen Inc AMGN reported fourth-quarter sales of $9.10 billion, up 11% year-over-year, beating the consensus of $8.9 billion.
AMGN's Q4 Earnings Beat, Obesity Candidate Under FDA Clinical Hold
AMGN beats fourth-quarter estimates for earnings and sales. FDA places clinical hold on a phase I study on its obesity candidate, AMG 513.
Amgen, Inc. (AMGN) Q4 2024 Earnings Call Transcript
Amgen, Inc. (NASDAQ:AMGN ) Q4 2024 Earnings Conference Call February 4, 2025 4:30 PM ET Company Participants Justin Claeys - VP, IR Robert Bradway - Chairman, CEO & President Murdo Gordon - EVP, Global Commercial Operations James Bradner - EVP, Research & Development Peter Griffith - EVP & CFO Conference Call Participants Yaron Werber - TD Cowen Courtney Breen - Bernstein Salveen Richter - Goldman Sachs David Amsellem - Piper Sandler Michael Yee - Jefferies Jay Olson - Oppenheimer Alex Hammond - Wolfe Research Terence Flynn - Morgan Stanley Dave Risinger - Leerink Partners Chris Schott - JPMorgan James Shin - Deutsche Bank Tim Anderson - Bank of America Merrill Lynch Conor MacKay - BMO Capital Markets Gregory Renza - RBC Capital Markets Mohit Bansal - Wells Fargo Operator My name is Julienne, and I will be your conference facilitator today for Amgen's Fourth Quarter and Full Year 2024 Financial Results Conference Call. [Operator Instructions] I would now like to introduce Justin Claeys, Vice President of Investor Relations.
Compared to Estimates, Amgen (AMGN) Q4 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Amgen (AMGN) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Amgen (AMGN) Q4 Earnings and Revenues Surpass Estimates
Amgen (AMGN) came out with quarterly earnings of $5.31 per share, beating the Zacks Consensus Estimate of $5.03 per share. This compares to earnings of $4.71 per share a year ago.
Amgen Surpasses Q4 Earnings Forecasts
Biotechnology specialist Amgen (AMGN 0.05%) reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 4, that topped analysts' consensus estimates. Analysts estimated Q4 adjusted EPS of $5.08 and revenue of $8.88 billion, but Amgen reported $5.31 in EPS and $9.1 billion in revenue, showcasing double-digit year-on-year growth in both metrics.
Amgen shares sink despite quarterly beat, FDA places obesity drug on clinical hold
CNBC's Angelica Peebles joins 'Closing Bell Overtime' with Amgen earnings.
Amgen profit beats estimates, next MariTide studies start by mid-year
Amgen posted a higher quarterly profit on Tuesday, driven by an 11% rise in product sales, and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but regulators have placed a hold on an early-stage trial of a different experimental weight-loss drug.
Will These 5 Big Drug Stocks Surpass Q4 Earnings Forecasts?
Let's look at five pharma and drug companies, MRK PFE, LLY, AMGN and BMY, which are scheduled to release their fourth-quarter 2024 results later this week.
Are These 5 Biotech Stocks Set to Beat Q4 Earnings Estimates?
Let us look at some biotech stocks, AMGN, CRSP, MRNA, SRPT and VRTX, which are poised to beat on fourth-quarter earnings.
Curious about Amgen (AMGN) Q4 Performance? Explore Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Amgen (AMGN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.
4 Healthcare Stocks Poised to Crush Q4 Earnings Estimates
Rising patient volumes, technological advancements, rate hikes and other factors are likely to have benefited healthcare players during Q4. Companies like AMGN, COR, HUM and ARDT are likely to outperform.
